Cargando…

Impact of COVID-19 on the Healthcare of Patients With Inflammatory Bowel Disease: A Comparison Between Epicenter vs. Non-epicenter Areas

Background and Aims: The COVID-19 pandemic poses a great challenge to healthcare. We aimed to investigate the impact of COVID-19 on the healthcare of patients with inflammatory bowel disease (IBD) in epicenter and non-epicenter areas. Methods: Patients with IBD from Hubei province (the epicenter of...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Yun, Zhang, Ying-Fan, Zhu, Liang-Ru, He, Jin-Shen, Tan, Jin-Yu, Tan, Nian-Di, Lin, Si-Nan, Lin, Xiao-Qing, Ghosh, Subrata, Chen, Min-Hu, Mao, Ren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734214/
https://www.ncbi.nlm.nih.gov/pubmed/33330534
http://dx.doi.org/10.3389/fmed.2020.576891
_version_ 1783622426157907968
author Qiu, Yun
Zhang, Ying-Fan
Zhu, Liang-Ru
He, Jin-Shen
Tan, Jin-Yu
Tan, Nian-Di
Lin, Si-Nan
Lin, Xiao-Qing
Ghosh, Subrata
Chen, Min-Hu
Mao, Ren
author_facet Qiu, Yun
Zhang, Ying-Fan
Zhu, Liang-Ru
He, Jin-Shen
Tan, Jin-Yu
Tan, Nian-Di
Lin, Si-Nan
Lin, Xiao-Qing
Ghosh, Subrata
Chen, Min-Hu
Mao, Ren
author_sort Qiu, Yun
collection PubMed
description Background and Aims: The COVID-19 pandemic poses a great challenge to healthcare. We aimed to investigate the impact of COVID-19 on the healthcare of patients with inflammatory bowel disease (IBD) in epicenter and non-epicenter areas. Methods: Patients with IBD from Hubei province (the epicenter of COVID-19) and Guangdong province (a non-epicenter area), China were surveyed during the pandemic. The questionnaire included change of medications (steroids, immunomodulators, and biologics), procedures (lab tests, endoscopy, and elective surgery), and healthcare mode (standard healthcare vs. telemedicine) during 1 month before and after the outbreak of COVID-19. Results: In total, 324 IBD patients from Guangdong province (non-epicenter) and 149 from Hubei province (epicenter) completed the questionnaire with comparable demographic characteristics. Compared to patients in Guangdong province (non-epicenter), significantly more patients in Hubei (epicenter) had delayed lab tests/endoscopy procedures [61.1% (91/149) vs. 25.3% (82/324), p < 0.001], drug withdrawal [28.6% (43/149) vs. 9.3% (30/324), p < 0.001], delayed biologics infusions [60.4% (90/149) vs. 19.1% (62/324), p < 0.001], and postponed elective surgery [16.1% (24/149) vs. 3.7% (12/324), p < 0.001]. There was an increased use of telemedicine after the outbreak compared to before the outbreak in Hubei province [38.9% (58/149) vs. 15.4% (23/149), p < 0.001], while such a significant increase was not observed in Guangdong province [21.9% (71/324) vs. 18.8% (61/324), p = 0.38]. Approximately two-thirds of IBD patients from both sites agreed that telemedicine should be increasingly used in future medical care. Conclusions: Our patient-based survey study in a real-world setting showed that COVID-19 resulted in a great impact on the healthcare of patients with IBD, and such an impact was more obvious in the epicenter compared to the non-epicenter area of COVID-19. Telemedicine offers a good solution to counteract the challenges in an unprecedented situation such as COVID-19.
format Online
Article
Text
id pubmed-7734214
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77342142020-12-15 Impact of COVID-19 on the Healthcare of Patients With Inflammatory Bowel Disease: A Comparison Between Epicenter vs. Non-epicenter Areas Qiu, Yun Zhang, Ying-Fan Zhu, Liang-Ru He, Jin-Shen Tan, Jin-Yu Tan, Nian-Di Lin, Si-Nan Lin, Xiao-Qing Ghosh, Subrata Chen, Min-Hu Mao, Ren Front Med (Lausanne) Medicine Background and Aims: The COVID-19 pandemic poses a great challenge to healthcare. We aimed to investigate the impact of COVID-19 on the healthcare of patients with inflammatory bowel disease (IBD) in epicenter and non-epicenter areas. Methods: Patients with IBD from Hubei province (the epicenter of COVID-19) and Guangdong province (a non-epicenter area), China were surveyed during the pandemic. The questionnaire included change of medications (steroids, immunomodulators, and biologics), procedures (lab tests, endoscopy, and elective surgery), and healthcare mode (standard healthcare vs. telemedicine) during 1 month before and after the outbreak of COVID-19. Results: In total, 324 IBD patients from Guangdong province (non-epicenter) and 149 from Hubei province (epicenter) completed the questionnaire with comparable demographic characteristics. Compared to patients in Guangdong province (non-epicenter), significantly more patients in Hubei (epicenter) had delayed lab tests/endoscopy procedures [61.1% (91/149) vs. 25.3% (82/324), p < 0.001], drug withdrawal [28.6% (43/149) vs. 9.3% (30/324), p < 0.001], delayed biologics infusions [60.4% (90/149) vs. 19.1% (62/324), p < 0.001], and postponed elective surgery [16.1% (24/149) vs. 3.7% (12/324), p < 0.001]. There was an increased use of telemedicine after the outbreak compared to before the outbreak in Hubei province [38.9% (58/149) vs. 15.4% (23/149), p < 0.001], while such a significant increase was not observed in Guangdong province [21.9% (71/324) vs. 18.8% (61/324), p = 0.38]. Approximately two-thirds of IBD patients from both sites agreed that telemedicine should be increasingly used in future medical care. Conclusions: Our patient-based survey study in a real-world setting showed that COVID-19 resulted in a great impact on the healthcare of patients with IBD, and such an impact was more obvious in the epicenter compared to the non-epicenter area of COVID-19. Telemedicine offers a good solution to counteract the challenges in an unprecedented situation such as COVID-19. Frontiers Media S.A. 2020-11-30 /pmc/articles/PMC7734214/ /pubmed/33330534 http://dx.doi.org/10.3389/fmed.2020.576891 Text en Copyright © 2020 Qiu, Zhang, Zhu, He, Tan, Tan, Lin, Lin, Ghosh, Chen and Mao. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Qiu, Yun
Zhang, Ying-Fan
Zhu, Liang-Ru
He, Jin-Shen
Tan, Jin-Yu
Tan, Nian-Di
Lin, Si-Nan
Lin, Xiao-Qing
Ghosh, Subrata
Chen, Min-Hu
Mao, Ren
Impact of COVID-19 on the Healthcare of Patients With Inflammatory Bowel Disease: A Comparison Between Epicenter vs. Non-epicenter Areas
title Impact of COVID-19 on the Healthcare of Patients With Inflammatory Bowel Disease: A Comparison Between Epicenter vs. Non-epicenter Areas
title_full Impact of COVID-19 on the Healthcare of Patients With Inflammatory Bowel Disease: A Comparison Between Epicenter vs. Non-epicenter Areas
title_fullStr Impact of COVID-19 on the Healthcare of Patients With Inflammatory Bowel Disease: A Comparison Between Epicenter vs. Non-epicenter Areas
title_full_unstemmed Impact of COVID-19 on the Healthcare of Patients With Inflammatory Bowel Disease: A Comparison Between Epicenter vs. Non-epicenter Areas
title_short Impact of COVID-19 on the Healthcare of Patients With Inflammatory Bowel Disease: A Comparison Between Epicenter vs. Non-epicenter Areas
title_sort impact of covid-19 on the healthcare of patients with inflammatory bowel disease: a comparison between epicenter vs. non-epicenter areas
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734214/
https://www.ncbi.nlm.nih.gov/pubmed/33330534
http://dx.doi.org/10.3389/fmed.2020.576891
work_keys_str_mv AT qiuyun impactofcovid19onthehealthcareofpatientswithinflammatoryboweldiseaseacomparisonbetweenepicentervsnonepicenterareas
AT zhangyingfan impactofcovid19onthehealthcareofpatientswithinflammatoryboweldiseaseacomparisonbetweenepicentervsnonepicenterareas
AT zhuliangru impactofcovid19onthehealthcareofpatientswithinflammatoryboweldiseaseacomparisonbetweenepicentervsnonepicenterareas
AT hejinshen impactofcovid19onthehealthcareofpatientswithinflammatoryboweldiseaseacomparisonbetweenepicentervsnonepicenterareas
AT tanjinyu impactofcovid19onthehealthcareofpatientswithinflammatoryboweldiseaseacomparisonbetweenepicentervsnonepicenterareas
AT tanniandi impactofcovid19onthehealthcareofpatientswithinflammatoryboweldiseaseacomparisonbetweenepicentervsnonepicenterareas
AT linsinan impactofcovid19onthehealthcareofpatientswithinflammatoryboweldiseaseacomparisonbetweenepicentervsnonepicenterareas
AT linxiaoqing impactofcovid19onthehealthcareofpatientswithinflammatoryboweldiseaseacomparisonbetweenepicentervsnonepicenterareas
AT ghoshsubrata impactofcovid19onthehealthcareofpatientswithinflammatoryboweldiseaseacomparisonbetweenepicentervsnonepicenterareas
AT chenminhu impactofcovid19onthehealthcareofpatientswithinflammatoryboweldiseaseacomparisonbetweenepicentervsnonepicenterareas
AT maoren impactofcovid19onthehealthcareofpatientswithinflammatoryboweldiseaseacomparisonbetweenepicentervsnonepicenterareas